Compare WIMI & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WIMI | CTXR |
|---|---|---|
| Founded | 2015 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.2M | 18.7M |
| IPO Year | 2019 | 2010 |
| Metric | WIMI | CTXR |
|---|---|---|
| Price | $1.34 | $0.76 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 127.5K | ★ 764.0K |
| Earning Date | 04-24-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | $1.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $0.47 |
| 52 Week High | $5.65 | $2.19 |
| Indicator | WIMI | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 63.60 |
| Support Level | $1.07 | $0.68 |
| Resistance Level | $1.40 | $0.99 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 80.00 | 82.16 |
WiMi Hologram Cloud Inc and its subsidiaries offer augmented reality (AR) based holographic services and products to cater to its customers. Its AR service and product offerings consist of holographic AR advertising services and holographic AR entertainment products. It is also into the semiconductor business, in which the company provides central processing algorithm services and computer chip products to enterprise customers and the sales of comprehensive solutions for central processing algorithms and related services with software and hardware integration. The company reports in three segments: AR advertising, AR entertainment, and Semiconductor. Its geographical segments are Mainland China, Hong Kong, and International.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.